Helena A. Yu
余海伦
MD
Associate Attending Physician, Thoracic Oncology Service胸部肿瘤科副主治医师
👥Biography 个人简介
Leading authority on EGFR exon 20 insertion mutations in NSCLC, a historically undertreated subgroup. Co-led pivotal CHRYSALIS and EXCLAIM trials of amivantamab and mobocertinib, establishing first approved therapies for this distinct molecular subset.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
EGFR Exon 20 Insertions
Co-led the CHRYSALIS trial demonstrating durable responses to amivantamab in EGFR exon 20 insertion NSCLC, leading to FDA approval and transforming treatment for this difficult-to-treat population.
Mobocertinib Development
Contributed to pivotal EXCLAIM extension cohort of the mobocertinib trial, which secured accelerated FDA approval for EGFR exon 20 insertion NSCLC after platinum-based chemotherapy.
Representative Works 代表性著作
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer (CHRYSALIS)
Journal of Clinical Oncology (2021)
Pivotal trial demonstrating 40% ORR with amivantamab in EGFR exon 20 insertion NSCLC, supporting FDA approval.
Mobocertinib in EGFR Exon 20 Insertion–Positive NSCLC After Platinum-Based Chemotherapy
JAMA Oncology (2021)
EXCLAIM cohort results showing 28% ORR supporting accelerated FDA approval of mobocertinib.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 余海伦 的研究动态
Follow Helena A. Yu's research updates
留下邮箱，当我们发布与 Helena A. Yu（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment